Royalty Pharma plc - Class A Ordinary Shares (NQ:RPRX)

57.16 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Royalty Pharma plc - Class A Ordinary Shares

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Jim Cramer: This Financial Stock Is A Buy, Core Scientific Is A 'Very Overvalued Situation' ↗

August 16, 2024

Jim Cramer discusses Snowflake, Royalty Pharma, Core Scientific and Ally Financial on "Mad Money Lightning Round."

Via Benzinga

RPRX Stock Earnings: Royalty Pharma Misses EPS, Misses Revenue for Q2 2024 ↗

August 08, 2024

RPRX stock results show that Royalty Pharma missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.

Via InvestorPlace

Royalty Pharma Reports Second Quarter 2024 Results

August 08, 2024

From Royalty Pharma plc

Via GlobeNewswire

Royalty Pharma Appoints Molly Sawaya as Executive Vice President, Head of Human Capital

July 24, 2024

From Royalty Pharma plc

Via GlobeNewswire

Royalty Pharma to Announce Second Quarter 2024 Financial Results on August 8, 2024

July 19, 2024

From Royalty Pharma plc

Via GlobeNewswire

NASDAQ:RPRX: good value for what you're paying. ↗

April 24, 2024

Investors should take notice ofROYALTY PHARMA PLC- CL A (NASDAQ:RPRX)—it offers a great deal for the fundamentals it presents.

Via Chartmill

Royalty Pharma Declares Third Quarter 2024 Dividend

July 17, 2024

From Royalty Pharma plc

Via GlobeNewswire

Cytokinetics' Wild Ride: Can Investors Forgive The Royalty Pharma Deal? ↗

July 11, 2024

CEO Robert Blum says there are key components to the funding arrangement with Royalty Pharma that investors are missing.

Via Investor's Business Daily

Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for June 2024 ↗

June 26, 2024

Selecting strong buy biotech stocks isn’t easy when most of them don’t make money. Here are three possibilities to meet this challenge.

Via InvestorPlace

7 Biotech Stocks to Buy on the Dip: June 2024 ↗

June 24, 2024

With health being a top priority over wealth generation, these biotech stocks to buy on the dip enjoy a sound framework for speculation.

Via InvestorPlace

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields ↗

June 12, 2024

Via Benzinga

June’s Biotech Boom: 3 Stocks to Buy for a Summertime Surge ↗

June 05, 2024

Biotech surge alert! Discover three biotech stocks to buy as they catch up with the market in the rest of 2024.

Via InvestorPlace

Royalty Pharma to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

June 04, 2024

From Royalty Pharma plc

Via GlobeNewswire

Royalty Pharma Announces Pricing of $1.5 Billion of Senior Unsecured Notes

June 03, 2024

From Royalty Pharma plc

Via GlobeNewswire

Why Is Agios Pharmaceuticals Stock Trading Higher On Tuesday? ↗

May 28, 2024

Agios Pharmaceuticals sells its 15% royalty rights on U.S. net sales of Servier's vorasidenib to Royalty Pharma for $905 million upon FDA approval.

Via Benzinga

Agios Pharmaceuticals Inks $905 Million Deal For Cancer Drug; Shares Poised To Break Out ↗

May 28, 2024

The stock is poised to break out of a cup-with-handle base after inking a deal for a cancer drug.

Via Investor's Business Daily

Royalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 Million

May 28, 2024

From Royalty Pharma plc

Via GlobeNewswire

Heart Disease-Focused Cytokinetics Operations Are On Track Despite Acquisition Uncertainty, Analysts Observe ↗

May 23, 2024

Unlock the latest on Royalty Pharma plc & Cytokinetics Inc.'s strategic funding collaboration for aficamten's commercialization and cardiovascular pipeline expansion.

Via Benzinga

Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline

May 22, 2024

From Royalty Pharma plc; Cytokinetics

Via GlobeNewswire

7 Dividend Stocks to Buy at a 52-Week Low ↗

May 20, 2024

For steady yields, not to mention rebound potential, consider the following seven dividend stocks at a 52-week low.

Via InvestorPlace

Royalty Pharma to Present at Upcoming Investor Conferences

May 13, 2024

From Royalty Pharma plc

Via GlobeNewswire

RPRX Stock Earnings: Royalty Pharma Misses EPS, Misses Revenue for Q1 2024 ↗

May 09, 2024

RPRX stock results show that Royalty Pharma missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.

Via InvestorPlace

Royalty Pharma Reports First Quarter 2024 Results

May 09, 2024

From Royalty Pharma plc

Via GlobeNewswire

Royalty Pharma to Acquire Royalty Interest in Sanofi’s Frexalimab

May 09, 2024

From Royalty Pharma plc

Via GlobeNewswire

Amgen Reports Better-Than-Expected Q1 Results, $50M Milestone Payment ↗

May 02, 2024

Amgen reported quarterly earnings of $3.96 per share which beat the analyst consensus estimate of $3.87 by 2.33%. The company said EPS decreased by 1% due to higher operating and interest expenses...

Via Benzinga

Royalty Pharma to Announce First Quarter 2024 Financial Results on May 9, 2024

April 19, 2024

From Royalty Pharma plc

Via GlobeNewswire

Royalty Pharma Declares Second Quarter 2024 Dividend

April 17, 2024

From Royalty Pharma plc

Via GlobeNewswire

3 Pharma Stocks to Sell in April Before They Crash & Burn ↗

April 11, 2024

Discover three pharma stocks to sell in April, facing challenges and signaling potential for significant downside.

Via InvestorPlace

Billionaire Bargain Bin: 3 Stocks the Forbes 400 Loves (That You’ve Never Heard Of) ↗

April 09, 2024

These Forbes 400 stocks have wealthy founders who run them with little fanfare or attention but are worth considering for your portfolio.

Via InvestorPlace

April’s Hidden Gems: 3 Overlooked Stocks to Freshen Up Your Portfolio ↗

April 09, 2024

Discover three overlooked stocks on Wall Street with the potential for growth and diversification this April.

Via InvestorPlace

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.